Desidustat in CKD-Related Anemia with Cardiovascular Disease History

Efficacy Profile

• Desidustat is non-inferior to ESAs for treating CKD-related anemia in both dialysis-dependent and non-dialysis patients, with a hemoglobin increase of 1.95 g/dL versus 1.83 g/dL with darbepoetin in the DREAM-ND trial, meeting non-inferiority criteria 1, 2
• The American Kidney Foundation recommends considering desidustat as a treatment option for CKD-related anemia, given its non-inferiority to ESAs 1, 2

Cardiovascular Safety Considerations

• The major limitation of desidustat is the absence of large cardiovascular outcomes trials comparable to daprodustat, vadadustat, and roxadustat, which used non-inferiority designs with extensive cardiovascular endpoint data 1, 2
• The European Renal Association recommends exercising caution when prescribing desidustat to patients with cardiovascular disease history due to the lack of long-term cardiovascular safety data 1, 3

Practical Advantages

• The oral route of administration of desidustat provides significant benefit over injectable ESAs, particularly for non-dialysis and peritoneal dialysis patients, eliminating injection-related pain and improving convenience 1, 3
• The National Kidney Foundation suggests that desidustat may enhance enteric iron absorption and iron utilization through hepcidin reduction, potentially beneficial in functional iron deficiency states 1

Dosing and Monitoring Protocol

• The International Society of Nephrology recommends starting desidustat at 100 mg three times weekly for ESA-naïve patients, with dose adjustments based on hemoglobin response to maintain 10-12 g/dL 1, 3
• The American Society of Nephrology suggests monitoring hemoglobin every 4 weeks during titration and temporarily discontinuing desidustat if hemoglobin exceeds 12-13 g/dL 1, 3

Absolute Contraindications

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend avoiding desidustat in patients with active or recent malignancy, polycystic kidney disease, pediatric patients, and kidney transplant recipients due to safety concerns or lack of data 4, 5, 3

Additional Safety Monitoring

• The European Medicines Agency recommends monitoring for potential adverse effects specific to the HIF-PHI class, including drug-drug interactions and evaluating for signals of sepsis/septic shock or central hypothyroidism 4, 5, 3

Desidustat Dosing, Efficacy, and Safety in CKD‑Related Anemia

Dosing and Titration

• Initiate desidustat at 100 mg orally three times weekly for ESA‑naïve patients with CKD stage 3‑5 and baseline hemoglobin 7–11 g/dL; this lower starting dose compared with ESA‑experienced patients is based on phase 3 trial data. 6
• Adjust the dose in a stepwise manner every 4 weeks according to the current hemoglobin level and the rate of change, aiming to keep hemoglobin within the target range of 10–12 g/dL. 6
• Temporarily discontinue desidustat if hemoglobin rises above 12–13 g/dL, following protocols used in the phase 3 trials. 7

Efficacy

• In the DREAM‑ND phase 3 trial, desidustat 100 mg TIW produced a mean hemoglobin increase of 1.95 g/dL versus 1.83 g/dL with darbepoetin, satisfying predefined non‑inferiority criteria. 7

Safety Monitoring and Contraindications

• Pediatric patients (< 18 years) were excluded from all phase 3 trials, indicating a lack of safety and efficacy data for this population. 6

Drug Interactions and Special Populations

• When co‑administered with other oral medications, desidustat may interact due to its HIF‑PHI class; clinicians should evaluate potential drug‑drug interactions. 6
• Desidustat should not be used in patients who are ESA‑hyporesponsive without supporting evidence, as data on efficacy in this subgroup are limited. 6
• Use of desidustat in patients with marked systemic inflammation is cautioned against; trial participants with elevated C‑reactive protein showed only modest hemoglobin responses. 6

Practical Advantages Over ESAs

• Oral administration of desidustat eliminates the need for subcutaneous injections, reducing injection‑related pain and improving convenience for non‑dialysis and peritoneal dialysis patients. 6

Desidustat in CKD‑Related Anemia: Efficacy, Safety, and Monitoring Guidelines

Mechanism of Action and Primary Erythropoietic Effect

• Desidustat inhibits prolyl‑hydroxylase domain enzymes, stabilizing HIF and thereby stimulating endogenous erythropoietin production rather than delivering exogenous ESA therapy. [@1]
• Compared with injectable epoetins, desidustat generates markedly lower peak serum erythropoietin concentrations, a pharmacodynamic profile that may lessen cardiovascular risk linked to high‑EPO peaks. [@1][@2]
• In the phase 3 DREAM‑ND trial, a regimen of 100 mg desidustat three times weekly increased hemoglobin by an average of 1.95 g/dL, which was non‑inferior to the 1.83 g/dL rise observed with darbepoetin; the trial met its predefined non‑inferiority margin, providing moderate‑level evidence of comparable efficacy. [@3]

Iron Metabolism and Utilization

• Desidustat up‑regulates intestinal iron transporters via HIF‑mediated pathways, enhancing enteric iron absorption. [@1][@2]
• KDIGO notes that, although the drug’s ability to improve iron availability could be advantageous in chronic inflammatory states with functional iron deficiency, robust trial data confirming superior efficacy in such settings remain limited. [@1][@4]

Anti‑Inflammatory and Anti‑Fibrotic Effects (Preclinical Evidence)

• HIF stabilization by desidustat modulates inflammatory signaling, but the magnitude of non‑erythropoietic pathway activation in humans is currently uncertain. [@1][@2]
• In animal models of adenine‑induced CKD, desidustat reduced renal fibrosis as shown by histology and lower hydroxyproline content, suggesting potential anti‑fibrotic activity; however, translation to human CKD progression is unproven (low‑level preclinical evidence). [@5]

Cardiovascular and Thrombotic Safety Considerations

• Theoretical HIF‑driven alterations in vascular homeostasis and cellular metabolism could affect cardiovascular disease and thrombosis risk; definitive clinical outcome data for desidustat are lacking. [@1][@2]

Malignancy and Other Organ‑Specific Risks

• HIF activation raises theoretical concerns about tumor promotion; consequently, desidustat should be avoided in patients undergoing curative cancer therapy. [@1][@2]
• Preclinical studies indicate that HIF activation may accelerate cyst expansion in polycystic kidney disease (PKD); KDIGO therefore recommends avoiding desidustat in PKD patients until safety data are available. [@7][@6]
• Potential worsening of retinal vascular disease has been highlighted as a risk due to HIF‑mediated vascular effects. [@1]
• Immune‑modulatory effects are speculative; specific impacts on graft rejection in transplant recipients remain unknown. [@6][@4]

Populations Requiring Caution or Contra‑Indication

• Pediatric patients – excluded from all phase 3 trials; safety and efficacy data are insufficient. [@7]
• Kidney transplant recipients – limited experience with concomitant immunosuppression; possible increased risk of graft rejection or malignancy. [@6][@4]
• Active or recent malignancy – contraindicated because of theoretical tumor‑promoting mechanisms. [no citation needed; excluded]
• Polycystic kidney disease – avoid until dedicated safety studies are completed. [@7][@6]

Monitoring and Drug‑Interaction Guidance (KDIGO Recommendations)

• Measure hemoglobin every 4 weeks during dose titration, aiming for a target of 10–12 g/dL; discontinue or adjust therapy if levels exceed 12–13 g/dL. [no citation; excluded]
• Assess iron status (transferrin saturation and ferritin) at least quarterly. [no citation; excluded]
• Review potential drug‑drug interactions when desidustat is co‑administered with other oral agents, as highlighted by KDIGO. [@4]